Healthcare · NSE: MOREPENLAB · BSE: 500288
Morepen Laboratories: how the business works
Morepen Laboratories makes medicine ingredients for drug companies and glucose meters for home use, earning ₹1,806 crore of revenue in FY26.
Follow Morepen Laboratories
Email me when Morepen Laboratories's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Morepen Laboratories Limited · Gurugram, Haryana · Founded 1984
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹1,806 cr
- Net profit, FY26
- ₹94.9 cr
- API and CDMO reactor capacity, Sep 2026
- 614 KL
- Incorporated
- 1984
- Promoter holding, 30 Sep 2026
- 35.65%
The short version
Morepen Laboratories in 5 points
1 · What it sells
Morepen Laboratories makes medicine ingredients (APIs) and contract-made ingredients for drug companies, plus glucose meters, test strips and blood-pressure monitors for home use, and its FY26 revenue was ₹1,806 crore.
2 · Who pays it
In FY26, buyers of APIs gave 53.32% of Morepen's consolidated sales, medical devices 33.14%, formulations 9.26% and OTC brands (until 31 Jul 2025) 4.28%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Morepen kept ₹5.1 as profit, including a ₹25.8 crore one-time gain on Dr. Morepen, and its operating profit before that gain (EBITDA) was 7.0% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Morepen reports one segment and gives no profit by business, though APIs were 53.32% of FY26 sales and the company said CDMO was 52% of its API plus CDMO revenue in Q2 FY27.
5 · The one thing to watch
The medical devices business, ₹597 crore of FY26 revenue, is to move into Morepen Medipath, a 51%-owned subsidiary in which promoter-group entities and relatives hold 42.89%.
Sources: From Morepen's FY26 annual report, its Q2 FY26 and Q4 FY26 results filings, its Q2 FY27 press release and its 20 May 2026 exchange filing · checked
Sources (6)
01Where the money goes · FY26
Where does ₹100 of Morepen Laboratories' money go?
Morepen Laboratories · FY26
Receipt for every ₹100
| Materials and goods bought for resale | ₹60.6 |
|---|---|
| Employee costs | ₹12.6 |
| Other running costs | ₹17.5 |
| Depreciation and interest | ₹2.9 |
| Income tax and minority holders' share | ₹1.4 |
| Kept as profit | ₹5.1 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 results and annual report: each line ÷ total money in (revenue of ₹1,806 crore, other income of ₹21.3 crore and the ₹25.8 crore one-time gain = ₹1,853 crore) × 100. The tax line includes ₹0.8 crore of profit belonging to minority holders.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Morepen Laboratories do?
Drug companies pay Morepen for medicine ingredients and households buy its glucose meters and test strips; materials take the biggest share, and ₹5.1 of every ₹100 that came in was left as profit in FY26.
- In FY26 medicine ingredients (APIs) were 53.32% of Morepen's consolidated sales, medical devices 33.14%, formulations 9.26% and OTC brands 4.28%.
- Of every ₹100 that came in during FY26, ₹60.6 went on materials, ₹17.5 on other running costs and ₹12.6 on staff (Cityfort calculation).
03Who pays it
Who pays Morepen Laboratories?
Drug makers buying APIs
53.3%
of revenue
Medicine makers in India and abroad buy Morepen's APIs; Morepen names Sandoz, Perrigo and Adamed among its customers. APIs were 53.32% of FY26 consolidated sales. CDMO orders from drug companies added revenue after FY26.
Households buying medical devices
33.1%
of revenue
People who check their blood sugar or blood pressure at home buy Morepen's meters, test strips and monitors. Devices were 33.14% of FY26 consolidated sales.
Formulation buyers
9.3%
of revenue
Companies that hire Morepen to make their medicines, doctors' prescriptions of Morepen Rx brands, and institutions. Formulations were 9.26% of FY26 consolidated sales.
OTC brand buyers (until 31 Jul 2025)
4.3%
of revenue
Shoppers buying Dr. Morepen's over-the-counter brands, counted only for the four months before Dr. Morepen stopped being a subsidiary. OTC was 4.28% of FY26 consolidated sales.
- Drug makers buying APIs53.3%
- Households buying medical devices33.1%
- Formulation buyers9.3%
- OTC brand buyers (until 31 Jul 2025)4.3%
How spread out the customers are
Morepen does not disclose its largest customers' share of sales. Infomerics said in Aug 2025 that Loratadine, Desloratadine and Montelukast together gave around 45–60% of API revenue. The ₹825 crore CDMO order comes from one unnamed company.
04How it makes money
How does Morepen Laboratories make money?
Total costs grew more slowly than sales in Q2 FY27, so more of each rupee was left as operating profit.
Revenue rose 81.4% from Q2 FY26 to Q2 FY27. Materials fell from 64.2% to 52.1% of revenue and employee costs from 13.8% to 10.7%, while other running costs rose from 14.6% to 20.7% (Cityfort calculations). EBITDA (profit before interest, tax and wear-and-tear of assets) was 16.5% of revenue, against 13.7% in Q2 FY26 including a one-time gain, or 7.5% without it. The company said in its Q2 FY27 press release (27 Oct 2026) that results were driven by "the scale-up of commercial CDMO supplies, an improving business mix and higher operating leverage".
EBITDA margin before one-off items, same quarter a year apart (Cityfort calculation)
7.5%16.5%
Q2 FY26 to Q2 FY27
- Morepen makes APIs in reactors in Himachal Pradesh; capacity reached 614 KL in Sep 2026.
- It sells older APIs such as Loratadine and Montelukast to drug makers, mostly abroad, where Infomerics says Chinese makers compete on price.
- Since Q1 FY27 it has also supplied a global pharma company under an order of about ₹825 crore.
- Morepen said CDMO was 52% of its API plus CDMO revenue in Q2 FY27.
- Glucose meters in use (about 20 million, the company says) need test strips, which the company calls recurring consumables.
- EBITDA was 16.5% of revenue in Q2 FY27 (Cityfort calculation).
↺ Step 6 feeds back into step 1.
05The numbers · Consolidated · ₹ crore
How has Morepen Laboratories done?
Revenue
₹1,806 crFY26
Revenue fell to ₹1,418 crore in FY23, rose to ₹1,812 crore in FY25 and was ₹1,806 crore in FY26, a year that counted Dr. Morepen for only four months; Q2 FY27 revenue of ₹747 crore was 81.4% above Q2 FY26.
₹ crore
See the numbers
Net profit
₹94.9 crFY26
Net profit fell from ₹118.0 crore in FY25 to ₹94.9 crore in FY26, which included a ₹25.8 crore one-time gain, and Q2 FY27 profit of ₹88.9 crore was 117.5% above Q2 FY26.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹5.3FY26
EBITDA was 8.4% of revenue (₹151 crore) in FY26 including the ₹25.8 crore one-time gain on Dr. Morepen, and 7.0% (₹126 crore) without it (Cityfort calculation), against 9.6% in FY25 and 16.5% in Q2 FY27.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
−₹128 crFY26
Free cash flow (operating cash flow minus capital spending) was below zero in every year from FY22 to FY26, minus ₹583 crore in total (Cityfort calculation), and was ₹37.8 crore in H1 FY27.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (20)
- Q4 FY22 and FY22 consolidated results (XBRL)
- Annual Report FY23 (38th) (NSE zip)
- Q4 FY23 and FY23 consolidated results (XBRL)
- Q4 FY24 and FY24 consolidated results (XBRL)
- Annual Report FY24 (39th)
- Q4 FY25 and FY25 (revised filing) consolidated results (XBRL)
- Annual Report FY25 (40th)
- Q4 FY26 and FY26 consolidated results (XBRL)
- Annual Report FY26 (41st), incl. BRSR FY26
- Q3 FY24 consolidated results (XBRL)
- Q1 FY25 consolidated results (XBRL)
- Q2 FY25 consolidated results (XBRL)
- Q3 FY25 consolidated results (XBRL)
- Q1 FY26 consolidated results (XBRL)
- Q2 FY26 consolidated results (XBRL)
- Q2 FY26 results (exceptional item note)
- Q3 FY26 consolidated results (XBRL)
- Q1 FY27 consolidated results (XBRL)
- Q2 FY27 consolidated results (XBRL)
- Q2 FY27 results (standalone + consolidated, unaudited)
06Who runs it
Who runs Morepen Laboratories, and did they deliver?
Sushil Suri
Chairman and Managing Director
Re-appointed for three years from 20 Oct 2026; shareholders approved it at the 26 Sep 2026 AGM. Paid 62.24 times the median employee's pay in FY26. His personal guarantee backs Morepen's unsecured term loans.
Sanjay Suri
Managing Director · since 2026
Managing Director from 1 Jul 2026, up to 12 Aug 2028, approved by shareholders at the 26 Sep 2026 AGM; earlier a whole-time director.
Ajay Kumar Sharma
Chief Financial Officer
A key managerial person on 31 Mar 2026.
Vipul Kumar Srivastava
Company Secretary
A key managerial person on 31 Mar 2026. The board then had four independent directors.
What they said, and what happened
2 too early to tell · 2 missed · 1 partly delivered · 1 delivered
Said on 12 Nov 2024
Sushil Suri said on the Q2 FY25 call: "we are targeting 15% EBITDA in the next three years and going up to 17%, 18% in the next five years".
Too early to tellWhat happened
EBITDA was 8.4% of revenue in FY26 including a one-time gain, 7.0% without it, and 16.5% in Q2 FY27 (Cityfort calculations). The three-year window has not ended.
Said on 6 Feb 2025
Chief financial officer Ajay Kumar Sharma said on the Q3 FY25 call that Morepen "should be touching around Rs. 1,900" crore in FY25; Sushil Suri added that this was not official guidance.
MissedWhat happened
FY25 revenue was ₹1,812 crore.
Said on 13 May 2025
Sushil Suri said on the Q4 FY25 call that in FY26 "every quarter should be INR500 crores".
MissedWhat happened
FY26 quarterly revenue was ₹425 crore, ₹412 crore, ₹484 crore and ₹485 crore.
Said on 13 May 2025
Sushil Suri said on the Q4 FY25 call: "within FY '26, we'll complete all 600 KL capacity".
Partly deliveredWhat happened
Capacity reached 614 KL on 7 Sep 2026, after FY26 ended. The company called this ahead of its timeline.
Said on 23 Feb 2026
Morepen said supplies under its ₹825 crore CDMO order would start in 4–5 months.
DeliveredWhat happened
Morepen reported ₹58 crore of CDMO revenue in Q1 FY27 (Apr–Jun 2026) and ₹253 crore in Q2 FY27.
Said on 27 Oct 2026
Sanjay Suri said the next capacity phase towards 800 KL was "targeted for completion by Q2 FY28".
Too early to tellWhat happened
Q2 FY28 ends on 30 Sep 2027.
Sources (15)
- Annual Report FY26 (41st), incl. BRSR FY26
- 41st AGM e-voting results (26 Sep 2026)
- Earnings call transcript Q2 FY25 (call 12 Nov 2024)
- Q4 FY26 and FY26 consolidated results (XBRL)
- Q2 FY27 consolidated results (XBRL)
- Earnings call transcript Q3 FY25 (call 6 Feb 2025)
- Q4 FY25 and FY25 (revised filing) consolidated results (XBRL)
- Earnings call transcript Q4 FY25 (call 13 May 2025)
- Q1 FY26 consolidated results (XBRL)
- Q2 FY26 consolidated results (XBRL)
- Q3 FY26 consolidated results (XBRL)
- Business update: API/CDMO reactor capacity 535 KL to 614 KL
- Press release: Q2 FY27 results
- Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company
- Press release: Q1 FY27 results
07What could go wrong
What could go wrong for Morepen Laboratories?
- Governance
Devices business moving to a subsidiary
Medical devices, 33.14% of FY26 consolidated sales, are to move into Morepen Medipath, 51% owned by Morepen; promoter-group entities and relatives hold 42.89%. Public institutions voted 99.37% against extending the transfer timeline; the resolution passed with 87.49% of votes cast, and the promoter group did not vote.
Watch Completion of the transfer and the final consideration, in exchange filings.
- Concentration
One large contract order
The ₹825 crore CDMO order comes from one unnamed company and was to be executed over about 12–15 months. Morepen said CDMO brought in ₹253 crore in Q2 FY27, 52% of API plus CDMO revenue.
Watch CDMO revenue each quarter and any new orders filed with the exchanges.
- Pricing
Price competition in older APIs
Infomerics said average API realisation fell from ₹21,886 in FY24 to ₹20,111 in FY25, and about 24% per kg over two years, as Chinese competitors cut prices in Loratadine, Montelukast and Desloratadine.
Watch Newer molecules' share of API revenue (25% in H1 FY27, company figure).
- Debt
Cash flow and rising borrowings
Free cash flow was below zero in every year from FY22 to FY26 (Cityfort calculation). Borrowings rose from ₹29.0 crore in Mar 2024 to ₹305 crore in Sep 2026, and the unsecured term loans carry the chairman's personal guarantee.
Watch Operating cash flow against capital spending, and borrowings, in each half-year filing.
- Regulation
Exchange surveillance
NSE's surveillance list of 12 Nov 2026 shows Morepen in Long Term ASM Stage IV, and its shares have traded in the trade-for-trade (BE) series since 13 Oct 2026.
Watch NSE's ASM list and the series the shares trade in.
- Legal
Pending legal cases
SEBI's appeal in the GDR matter and Morepen's section 408 appeal are pending in the Supreme Court. Two Companies Act prosecutions and nine revision applications are pending in court.
Watch Court outcomes reported in the annual report or exchange filings.
- Currency
Currency moves
Exports were 44.6% of FY26 consolidated sales (Cityfort calculation), and Morepen said they were about half of sales in H1 FY27.
Watch The rupee against the US dollar and the export share in each results release.
Sources (12)
- Annual Report FY26 (41st), incl. BRSR FY26
- Q4 FY26 and FY26 audited results; BTA second addendum (Reg. 30)
- Transfer of 9% of Morepen Medipath Ltd to Mr Anubhav Suri (stake 60% to 51%)
- 41st AGM e-voting results (26 Sep 2026)
- Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company
- Press release: Q2 FY27 results
- Infomerics rating rationale: IVR A-/Stable, long-term bank facilities Rs 225 cr
- Q4 FY24 and FY24 consolidated results (XBRL)
- Q4 FY26 and FY26 consolidated results (XBRL)
- Q2 FY27 consolidated results (XBRL)
- NSE ASM list: MOREPENLAB in Long Term ASM Stage IV (as of 12 Nov 2026)
- NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026
08Supporters and critics
What do supporters and critics point to?
What supporters point to
- Q2 FY27 revenue of ₹747 crore was 81.4% above Q2 FY26, and net profit of ₹88.9 crore was 117.5% higher.
- Morepen said CDMO revenue reached ₹253 crore in Q2 FY27 and that its ₹825 crore order is in regular commercial supply.
- Medical devices sold ₹597 crore in FY26, up 20.13%.
- No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
- The Himachal Pradesh High Court quashed a ₹117.94 crore CGST show-cause notice on 12 Oct 2026.
What critics point to
- Free cash flow was below zero in every year from FY22 to FY26, minus ₹583 crore in total, and borrowings reached ₹305 crore in Sep 2026.
- The devices business is to move into a 51%-owned subsidiary in which promoter-group entities and relatives hold 42.89%; public institutions voted 99.37% against extending the timeline, and the resolution passed with 87.49% of votes cast; the promoter group did not vote.
- Morepen has held no earnings call since May 2025, and its press releases headline total income or standalone figures.
- NSE's surveillance list of 12 Nov 2026 shows the stock in Long Term ASM Stage IV, and it has traded with trade-for-trade settlement since 13 Oct 2026.
- Infomerics said API realisation fell about 24% per kg over two years under Chinese price competition.
09What to watch next
What should you watch next at Morepen Laboratories?
Next event
Q3 FY27 results
Date not announced yet.
Devices transfer
Whether the move of the medical devices business into the 51%-owned Medipath completes, and at what final consideration (₹197.10 crore before adjustments).
CDMO after the big order
CDMO revenue was ₹253 crore in Q2 FY27; the ₹825 crore order was to run for about 12–15 months from the date of award (23 Feb 2026).
Debt and cash flow
Borrowings were ₹305 crore on 30 Sep 2026, and H1 FY27 free cash flow was ₹37.8 crore after five years below zero.
10Key facts
Key facts about Morepen Laboratories
- What does Morepen Laboratories do?
- Morepen Laboratories Ltd is a pharmaceutical company, incorporated in 1984, with four plants in India and a corporate office in Gurugram. Morepen makes active pharmaceutical ingredients (APIs, the chemicals in medicines that do the work), makes ingredients to order for drug companies, and sells glucose meters, test strips and blood-pressure monitors; its FY26 revenue was ₹1,806 crore.
- How does Morepen Laboratories make money?
- Morepen Laboratories earns most of its money selling APIs: in FY26 APIs were 53.32% of consolidated sales, medical devices 33.14%, formulations 9.26% and OTC brands 4.28%, the last only until Dr. Morepen Ltd stopped being a subsidiary on 31 Jul 2025. Morepen said contract manufacturing (CDMO) brought in ₹253 crore in Q2 FY27.
- Who are Morepen Laboratories' customers?
- Morepen Laboratories sells APIs to drug makers in India and abroad and names Sandoz, Perrigo and Adamed among its API customers; it also sells glucose meters, test strips and blood-pressure monitors for home use. In FY26 India gave 55.4% of Morepen's consolidated sales and exports 44.6% (Cityfort calculation from the FY26 annual report).
- How big is Morepen Laboratories?
- In FY26 Morepen Laboratories earned ₹1,806 crore of revenue and ₹94.9 crore of net profit, against ₹1,812 crore and ₹118.0 crore in FY25; FY26 profit included a ₹25.8 crore one-time gain. Morepen had 1,919 permanent employees and workers on 31 Mar 2026.
- Who owns Morepen Laboratories?
- On 30 Sep 2026 the promoter group held 35.65% of Morepen Laboratories, with no shares pledged. Foreign portfolio investors held 3.43%, Indian institutions 1.71% and other shareholders, mostly individuals and companies, 59.21%.
- How did Morepen Laboratories do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Morepen Laboratories' revenue was ₹747 crore, up 81.4% from ₹412 crore in Q2 FY26, and net profit was ₹88.9 crore, up 117.5% from ₹40.9 crore; Q2 FY26 profit included a ₹25.8 crore one-time gain.
- What happened to Dr. Morepen?
- Morepen Laboratories' holding in Dr. Morepen Ltd, which owns OTC brands such as Burnol, fell to 19.94% on 31 Jul 2025, so Dr. Morepen stopped being a subsidiary. Morepen booked a ₹25.8 crore one-time gain in Q2 FY26, and OTC brands were 4.28% of its FY26 consolidated sales.
- Does Morepen Laboratories have debt?
- Morepen Laboratories had ₹305 crore of borrowings on 30 Sep 2026, up from ₹195 crore on 31 Mar 2026, and ₹271 crore of cash, bank balances and current investments. Infomerics rated its bank facilities IVR A- (Stable) on 22 Aug 2025.
- What dividend does Morepen Laboratories pay?
- Morepen Laboratories declared a dividend of ₹0.20 a share for FY25 and, at the 26 Sep 2026 AGM, ₹0.20 a share for FY26. The FY25 dividend, paid in FY26, came to ₹10.9 crore.
Sources (10)
- Annual Report FY26 (41st), incl. BRSR FY26
- Q4 FY26 and FY26 consolidated results (XBRL)
- Press release: Q2 FY27 results
- Q4 FY25 and FY25 (revised filing) consolidated results (XBRL)
- Shareholding pattern as of 2026-09-30 (XBRL)
- Q2 FY27 consolidated results (XBRL)
- Q2 FY26 consolidated results (XBRL)
- Q2 FY26 results (exceptional item note)
- Infomerics rating rationale: IVR A-/Stable, long-term bank facilities Rs 225 cr
- 41st AGM e-voting results (26 Sep 2026)
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
11What it sells
11What it sells
What does Morepen Laboratories sell?
Medicine ingredients (APIs)
Active pharmaceutical ingredients (APIs), the chemicals in a medicine that do the work, such as Loratadine, Montelukast, Desloratadine, Fexofenadine, Atorvastatin and Rosuvastatin. The API business sold ₹983 crore in FY26. Newer molecules such as Edoxaban and Linagliptin brought in ₹56.4 crore, up from ₹25.5 crore in FY25.
Contract manufacturing (CDMO)
CDMO means making ingredients to order for another drug company. In Feb 2026 Morepen won an order worth about ₹825 crore from an unnamed global pharma company. Morepen said CDMO brought in ₹58 crore in Q1 FY27 and ₹253 crore in Q2 FY27.
Home medical devices
Glucose meters and test strips for people with diabetes, and blood-pressure monitors. The business sold ₹597 crore in FY26, up 20.13%; glucose monitoring was ₹459 crore of it. Morepen says about 20 million of its glucose meters are in use, and it sells about 500 million strips a year.
Finished medicines (formulations)
Tablets and other medicines made for other companies (₹84.9 crore in FY26), branded prescription medicines through Morepen Rx (₹54.5 crore) and supplies to institutions (₹48.3 crore).
What it does
- Does: Makes APIs and devices at four plants in India
- Does: Exports: 44.6% of FY26 consolidated sales went outside India (Cityfort calculation)
- Does: Launched its first US prescription medicine, Desloratadine tablets, on 9 Nov 2026 through its US subsidiary
What it does not do
- Does not: No longer owns OTC brands such as Burnol: they left the group with Dr. Morepen Ltd on 31 Jul 2025
- Does not: Does not report profit by business: it reports a single segment, Pharmaceuticals
- Does not: Does not name its CDMO customers
12How the money flows
12How the money flows · FY26
How does money flow through Morepen Laboratories?
Money in
- Revenue from operations₹1,806 cr
- One-time gain when Dr. Morepen stopped being a subsidiary (exceptional item)₹25.8 cr
- Other income₹21.3 cr
The company
Morepen Laboratories
₹1,853 cr came in
Money out
- Materials and goods bought for resale₹1,123 cr
- Employee costs₹233 cr
- Other running costs₹324 cr
- Depreciation and interest₹52.8 cr
- Income tax₹24.3 cr
- Profit belonging to minority holders₹0.8 cr
- Net profit₹94.9 cr
- In FY26 Morepen sold ₹1,806 crore of goods and earned ₹21.3 crore of other income, plus a ₹25.8 crore one-time gain on Dr. Morepen.
- Materials and goods bought for resale took ₹1,123 crore, the biggest cost.
- Employees took ₹233 crore and other running costs ₹324 crore.
- Depreciation and interest took ₹52.8 crore, income tax ₹24.3 crore and minority holders ₹0.8 crore.
- What was left was ₹94.9 crore of net profit for Morepen's shareholders.
13What it needs to run
13What it needs to run
What does Morepen Laboratories need to run?
Plants and reactors
Four plants, all in India, including API sites at Baddi and Masulkhana in Himachal Pradesh. API and CDMO reactor capacity rose from about 535 KL (kilolitres of reactor volume) to 614 KL on 7 Sep 2026.
Regulator approvals
Buyers of APIs need plants approved by regulators. Morepen lists US FDA approvals for Loratadine (1999), Desloratadine (2010), Montelukast (2015) and Atorvastatin (2018) APIs.
Raw materials
Materials and goods bought for resale took ₹1,123 crore in FY26, 62.2% of revenue (Cityfort calculation). Infomerics said Morepen passes cost increases to customers only with a time lag.
People
1,314 permanent employees and 605 permanent workers on 31 Mar 2026, plus 1,150 non-permanent workers.
Capital spending
Morepen spent ₹214 crore on plants, equipment and intangibles (including leased assets) in FY25 and ₹161 crore in FY26, more than it made from operations in both years.
14Where it sells
14Where it sells · FY26
Where does Morepen Laboratories sell?
- India55.4%
- Outside India (exports)44.6%
Sources (1)
15Where growth could come from
15Where growth could come from
Where could Morepen Laboratories' growth come from?
Sanjay Suri, Managing Director, said in the Q2 FY27 press release (27 Oct 2026) that civil work had begun on the next phase towards 800 KL of reactor capacity, "targeted for completion by Q2 FY28". Morepen's NSE filings to 12 Nov 2026 show no earnings call after 13 May 2025.
Contract manufacturing (CDMO)
Working₹253 crore, Q2 FY27 (company)
Morepen won an order of about ₹825 crore in Feb 2026, to be executed over about 12–15 months. It said CDMO revenue was ₹58 crore in Q1 FY27 and ₹253 crore in Q2 FY27, 52% of API plus CDMO revenue.
Status: Working, on track against what the company said.
Medical devices
Working₹597 crore, FY26 (up 20.13%)
Morepen said device revenue was ₹208 crore in Q2 FY27, up 65%. The business is to move into Morepen Medipath, a 51%-owned subsidiary (see Governance).
Status: Working, on track against what the company said.
Newer APIs
Working₹56.4 crore, FY26 (₹25.5 crore in FY25)
Molecules such as Edoxaban, Linagliptin, Saxagliptin and Vonoprazan. Morepen said newer molecules rose from 14% of API revenue in H1 FY26 to 25% in H1 FY27.
Status: Working, on track against what the company said.
Reactor capacity
Working614 KL, Sep 2026
Capacity rose from about 535 KL to 614 KL on 7 Sep 2026. Morepen said on 27 Oct 2026 it targets 800 KL by Q2 FY28; its 4 Aug 2026 release set out a roadmap to 1,200 KL by FY30.
Status: Working, on track against what the company said.
Exports
Working₹654 crore, H1 FY27 (company)
Morepen said exports were about half of sales in H1 FY27, against 35% in H1 FY26. Exports were 44.6% of FY26 consolidated sales (Cityfort calculation).
Status: Working, on track against what the company said.
US prescription medicines
NewFirst launch, 9 Nov 2026
Morepen's US subsidiary launched Desloratadine tablets, its first US prescription generic, and Morepen filed its first US generic application (ANDA), for Sitagliptin tablets, in Q2 FY27.
Status: New, recently announced.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (9)
- Press release: Q2 FY27 results
- Earnings call transcript Q4 FY25 (call 13 May 2025)
- Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company
- Press release: Q1 FY27 results
- Annual Report FY26 (41st), incl. BRSR FY26
- Transfer of 9% of Morepen Medipath Ltd to Mr Anubhav Suri (stake 60% to 51%)
- Business update: API/CDMO reactor capacity 535 KL to 614 KL
- Investor presentation Q2 and H1 FY27
- Press release: US prescription generics launch (Desloratadine tablets); first ANDA (Sitagliptin) filed
16Financial strength and debt
16Financial strength · 30 Sep 2026
How much debt does Morepen Laboratories have?
- Total debt₹305 cr
- Cash and investments₹271 cr
- Net debt (debt minus cash)₹34 cr
- Net worth (shareholders' money)₹1,381 cr
- Debt to equity
- 0.22×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings rose from ₹29.0 crore on 31 Mar 2024 to ₹194.7 crore on 31 Mar 2026 and ₹305 crore on 30 Sep 2026. They exclude lease liabilities (₹13.2 crore on 31 Mar 2026).
- Unsecured term loans were ₹134.1 crore on 31 Mar 2026; in FY26 Kookmin, Woori and Hana banks lent ₹130 crore of three-year term loans. The unsecured loans carry the personal guarantee of chairman Sushil Suri.
- In H1 FY27 operating cash flow was ₹127.5 crore and capital spending ₹89.7 crore, leaving ₹37.8 crore of free cash flow (Cityfort calculation).
- The Himachal Pradesh High Court quashed a ₹117.94 crore CGST show-cause notice on 12 Oct 2026; the company said the related ₹317.37 crore contingent liability, including interest and penalty, no longer exists. The filing does not discuss an appeal.
- Debt to equity = borrowings ÷ equity of ₹1,381 crore (Cityfort calculation); the company's own Q2 FY27 presentation gives 0.23x.
Sources (7)
- Q2 FY27 consolidated results (XBRL)
- Q4 FY24 and FY24 consolidated results (XBRL)
- Q4 FY26 and FY26 consolidated results (XBRL)
- Annual Report FY26 (41st), incl. BRSR FY26
- Q2 FY27 results (standalone + consolidated, unaudited)
- HP High Court quashes CGST show-cause notice (Rs 117.94 cr)
- Investor presentation Q2 and H1 FY27
17Who owns it
17Who owns it · Q2 FY27
Who owns Morepen Laboratories?
- Promoters (founders or parent company)35.7%
- Foreign institutions (FII)3.4%
- Indian institutions (DII)1.7%
- Public and others59.2%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (12)
- Shareholding pattern as of 2023-12-31 (XBRL)
- Shareholding pattern as of 2024-03-31 (XBRL)
- Shareholding pattern as of 2024-06-30 (XBRL)
- Shareholding pattern as of 2024-09-30 (XBRL)
- Shareholding pattern as of 2024-12-31 (XBRL)
- Shareholding pattern as of 2025-03-31 (XBRL)
- Shareholding pattern as of 2025-06-30 (XBRL)
- Shareholding pattern as of 2025-09-30 (XBRL)
- Shareholding pattern as of 2025-12-31 (XBRL)
- Shareholding pattern as of 2026-03-31 (XBRL)
- Shareholding pattern as of 2026-06-30 (XBRL)
- Shareholding pattern as of 2026-09-30 (XBRL)
18What it does with profit
18What it does with profit
What does Morepen Laboratories do with its profit?
Dividend per share
₹0.20FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Money raised · 5 Aug 2024
Qualified institutional placement (QIP): 3,67,84,991 new shares at ₹54.37 each. The promoter holding fell from 38.22% to 35.65%.
₹200 cr
Sources (6)
19Governance signals
19Governance signals
What do Morepen Laboratories' governance filings show?
- Auditor
- S.P. Babuta & Associates, since 2022
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- In FY26 Morepen sold ₹49.2 crore of inventories to related entities, paid key managers ₹8.1 crore and other Suri family members ₹13.0 crore, and received ₹30.65 crore from related entities for Dr. Morepen shares. Consolidated figures from the FY26 annual report.
- Credit rating
- Infomerics Valuation and Rating IVR A- (Stable) on ₹225 crore of long-term bank facilities (outlook Stable), 22 Aug 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
surveillance · 12 Nov 2026
NSE surveillance: Long Term ASM Stage IV
NSE's Additional Surveillance Measure (ASM) list of 12 Nov 2026 shows Morepen in Long Term ASM Stage IV. Since 13 Oct 2026 the shares trade in NSE's BE series (trade-for-trade), where every trade is settled by delivery.
related party · 26 May 2026
Medical devices business to move to a 51%-owned subsidiary
Morepen is transferring its medical devices business (₹597 crore of FY26 revenue) by slump sale to Morepen Medipath, its subsidiary. The company filed that promoter-group entities and relatives hold 42.89% of Medipath, and called the deal arm's length. The consideration is ₹197.10 crore, subject to closing adjustments. The transfer was not complete at 30 Sep 2026.
related party · 26 Sep 2026
Medipath stake moved to an executive; shareholder vote
On 20 May 2026 Morepen transferred 1,62,000 Medipath shares to Anubhav Suri, head of the medical devices business, cutting its stake from 60% to 51%, at a mutually agreed price. At the 26 Sep 2026 AGM, 87.49% of votes cast approved extending the transfer timeline; public institutions voted 99.37% against, and the promoter group did not vote.
related party · 31 Jul 2025
Dr. Morepen diluted through related parties
Morepen's stake in Dr. Morepen Ltd fell from 100% to 80% in Mar 2025, when related parties converted warrants, then to 19.94% on 31 Jul 2025, when Dr. Morepen issued new shares to acquire Groom Town, a related entity, and Morepen sold Dr. Morepen shares to related entities for ₹30.65 crore.
regulatory · 15 Apr 2021
SEBI order on the GDR issue: set aside, appeal pending
SEBI's order of 24 Sep 2019 restrained Morepen from the securities market for one year in a matter relating to its GDR issue. The Securities Appellate Tribunal set the order aside on 15 Apr 2021. SEBI's appeal is pending in the Supreme Court.
other · 14 Jan 2026
Old Companies Act cases
Of 27 prosecutions by the Registrar of Companies and the Union of India under section 235 of the 1956 Act, 15 were compounded, 10 dismissed on 7 Nov 2025 as time-barred and 2 are pending; the Union of India filed revision applications on 14 Jan 2026. Morepen's appeal over government directors under section 408 is pending in the Supreme Court.
other · 20 Jul 2026
Surrendered shares still listed
Former fixed-deposit holders surrendered 50,62,872 shares for cancellation in 2019–21 under an NCLT order of 12 Mar 2018. The board cancelled them, but the exchanges have not approved removing them from listed capital, citing non-compliance with the NCLT order in entirety.
disclosure · 12 Nov 2026
No earnings call since May 2025; headline figures differ
Morepen's NSE filings show no earnings call after 13 May 2025, and it reports one segment. Its press releases give total income as revenue (₹755 crore in Q2 FY27, against revenue from operations of ₹747 crore), and the Q4 FY26 release gave standalone figures.
Sources (14)
- Annual Report FY26 (41st), incl. BRSR FY26
- Infomerics rating rationale: IVR A-/Stable, long-term bank facilities Rs 225 cr
- Credit rating intimation (Infomerics IVR A-/Stable)
- NSE ASM list: MOREPENLAB in Long Term ASM Stage IV (as of 12 Nov 2026)
- NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026
- Q4 FY26 and FY26 audited results; BTA second addendum (Reg. 30)
- Q2 FY27 results (standalone + consolidated, unaudited)
- Transfer of 9% of Morepen Medipath Ltd to Mr Anubhav Suri (stake 60% to 51%)
- 41st AGM e-voting results (26 Sep 2026)
- Dr. Morepen Ltd: warrants converted by related parties, stake 100% to 80%
- Earnings call transcript Q4 FY25 (call 13 May 2025)
- Press release: Q2 FY27 results
- Press release: Q4 FY26 results (standalone headline figures)
- Q2 FY27 consolidated results (XBRL)
20What the market paid
20What the market paid · price as of 11 Nov 2026
What did the market pay for Morepen Laboratories on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹96.74, the NSE closing price in the BE (trade-for-trade) series. Market value = price × 547,953,699 listed shares = ₹5,301 crore (Cityfort calculation); the count includes the 50,62,872 surrendered shares. P/E (price ÷ earnings) = market value ÷ net profit of the last four quarters (Q3 FY26 to Q2 FY27, ₹188.5 crore) = 28.1; on FY26 profit it is 55.9. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹1,381 crore) = 3.8. Dividend yield = FY26 dividend of ₹0.20 ÷ price = 0.21%.
- Share price
- ₹96.74
- Market value (market cap)
- ₹5,301 cr
- P/E
- 28.1×
- P/B
- 3.8×
Source: NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026; Shareholding pattern as of 2026-09-30 (XBRL); Annual Report FY26 (41st), incl. BRSR FY26 and 4 more
Sources (7)
- NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026
- Shareholding pattern as of 2026-09-30 (XBRL)
- Annual Report FY26 (41st), incl. BRSR FY26
- Q3 FY26 consolidated results (XBRL)
- Q4 FY26 and FY26 consolidated results (XBRL)
- Q1 FY27 consolidated results (XBRL)
- Q2 FY27 consolidated results (XBRL)
21How it got here
21How it got here
How did Morepen Laboratories get here?
1984
Milestone
Incorporated
Morepen was incorporated in 1984 and began operations on 1 Dec 1984. Its annual report names the late K.B. Suri as founder and Ampicillin as its first API.
1992
Milestone
Listed
Morepen held its IPO and listed on the stock exchanges.
1999
Milestone
US FDA approval for Loratadine
The Loratadine API won US FDA approval, and Morepen launched a diagnostics division.
2001
Business-model change
OTC brands
Morepen launched its Dr. Morepen OTC brand and bought the Burnol brand.
2018
Crisis
Fixed-deposit dues
An NCLT order of 12 Mar 2018 required Morepen to repay eligible fixed-deposit holders; 50,62,872 shares were surrendered in 2019–21 and are still in listed capital.
2024
Milestone
₹200 crore share placement
Morepen raised ₹200 crore from institutions at ₹54.37 a share in Aug 2024.
2025
Business-model change
Dr. Morepen leaves the group
Dr. Morepen Ltd, with its OTC brands, stopped being a subsidiary on 31 Jul 2025, after Morepen's stake fell to 19.94%.
2026
Business-model change
₹825 crore CDMO order
In Feb 2026 Morepen won an order of about ₹825 crore from a global pharma company; supplies began in Q1 FY27.
2026
Milestone
614 KL capacity and first US medicine
Reactor capacity reached 614 KL on 7 Sep 2026, and the US subsidiary launched Desloratadine tablets on 9 Nov 2026.
Sources (7)
- Annual Report FY26 (41st), incl. BRSR FY26
- QIP allotment: 3,67,84,991 shares at Rs 54.37 (Rs 200 cr)
- Q2 FY26 results (exceptional item note)
- Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company
- Press release: Q1 FY27 results
- Business update: API/CDMO reactor capacity 535 KL to 614 KL
- Press release: US prescription generics launch (Desloratadine tablets); first ANDA (Sitagliptin) filed
22Sources and changes
Where every number on this page comes from
Sources (52 documents)
- S1Annual Report FY26 (41st), incl. BRSR FY26 · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 2 Sep 2026
- S2Annual Report FY25 (40th) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Aug 2025
- S3Annual Report FY24 (39th) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Sep 2024
- S4Annual Report FY23 (38th) (NSE zip) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Sep 2023
- S5Q2 FY27 results (standalone + consolidated, unaudited) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S6Q2 FY27 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S7Q1 FY27 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Aug 2026
- S8Q4 FY26 and FY26 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 May 2026
- S9Q3 FY26 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 10 Feb 2026
- S10Q2 FY26 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Nov 2025
- S11Q1 FY26 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 6 Aug 2025
- S12Q4 FY25 and FY25 (revised filing) consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 May 2025
- S13Q3 FY25 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 6 Feb 2025
- S14Q2 FY25 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Nov 2024
- S15Q1 FY25 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Aug 2024
- S16Q4 FY24 and FY24 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 21 May 2024
- S17Q3 FY24 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 31 Jan 2024
- S18Q4 FY23 and FY23 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 May 2023
- S19Q4 FY22 and FY22 consolidated results (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 5 May 2022
- S20Q4 FY26 and FY26 audited results; BTA second addendum (Reg. 30) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 May 2026
- S21Q2 FY26 results (exceptional item note) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Nov 2025
- S23Investor presentation Q2 and H1 FY27 · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S25Press release: Q2 FY27 results · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S26Press release: Q1 FY27 results · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Aug 2026
- S27Press release: Q4 FY26 results (standalone headline figures) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 May 2026
- S28Earnings call transcript Q4 FY25 (call 13 May 2025) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 May 2025
- S29Earnings call transcript Q3 FY25 (call 6 Feb 2025) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Feb 2025
- S30Earnings call transcript Q2 FY25 (call 12 Nov 2024) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Nov 2024
- S32Infomerics rating rationale: IVR A-/Stable, long-term bank facilities Rs 225 cr · Infomerics Valuation and Rating Ltd · Tier 2: rating agency or regulator · 22 Aug 2025
- S33Credit rating intimation (Infomerics IVR A-/Stable) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 22 Aug 2025
- S34Shareholding pattern as of 2026-09-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Oct 2026
- S35Shareholding pattern as of 2026-06-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Jul 2026
- S36Shareholding pattern as of 2026-03-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 10 Apr 2026
- S37Shareholding pattern as of 2025-12-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Jan 2026
- S38Shareholding pattern as of 2025-09-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Oct 2025
- S39Shareholding pattern as of 2025-06-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Jul 2025
- S40Shareholding pattern as of 2025-03-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Apr 2025
- S41Shareholding pattern as of 2024-12-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Jan 2025
- S42Shareholding pattern as of 2024-09-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Oct 2024
- S44Shareholding pattern as of 2024-06-30 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Jul 2024
- S45Shareholding pattern as of 2024-03-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Apr 2024
- S46Shareholding pattern as of 2023-12-31 (XBRL) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Jan 2024
- S47Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Feb 2026
- S48Business update: API/CDMO reactor capacity 535 KL to 614 KL · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Sep 2026
- S49Press release: US prescription generics launch (Desloratadine tablets); first ANDA (Sitagliptin) filed · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Nov 2026
- S50HP High Court quashes CGST show-cause notice (Rs 117.94 cr) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Oct 2026
- S51Transfer of 9% of Morepen Medipath Ltd to Mr Anubhav Suri (stake 60% to 51%) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 20 May 2026
- S53Dr. Morepen Ltd: warrants converted by related parties, stake 100% to 80% · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 31 Mar 2025
- S54QIP allotment: 3,67,84,991 shares at Rs 54.37 (Rs 200 cr) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 5 Aug 2024
- S5541st AGM e-voting results (26 Sep 2026) · Morepen Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 Sep 2026
- S57NSE ASM list: MOREPENLAB in Long Term ASM Stage IV (as of 12 Nov 2026) · NSE · Tier 1: company or exchange filing · 12 Nov 2026
- S58NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026 · NSE · Tier 1: company or exchange filing · 11 Nov 2026
Changes to this page (v1 · 12 Nov 2026)
- v1 · 12 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.